Qiagen N.V. NYQ · QGEN
Price alert —
Sign in to get a one-time email the moment QGEN crosses your price. Free accounts included.
Sign in / create a free accountQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
QGEN last traded at $41.15, down 0.9% on the day; that's in the middle part of its 52-week range ($32.53–$57.82). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +1.11 ATR from EMA21 — bearish engulfing
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · Bearish engulfing — body fully covers prior green bar
- · RSI hook from overbought (61)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 61), the trend is strong (ADX 30), and trading is light at 0.7× normal volume. On the business side, revenue is growing 2% year over year and the business keeps about 11 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $11.89 (fair range $12–$37); today's price sits 249% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 2.05 (antifragile)
- ✓ Current ratio 3.90 (antifragile)
- ✓ Debt/equity 0.66 (antifragile)
- ✓ Positive retained earnings
- ⚠ Debt exceeds cash
- ⚠ Receivables growing faster than revenue
Price implies ~19% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
QGEN is a $8.5 billion company, priced at 21× last year's earnings, and it moves more calmly than the market (beta 0.6).
Options idea
See more →About
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and ma…